LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.
With successful conclusion of this Phase III clinical program, LibiGel could be the first product approved by the FDA for women with low sexual desire, HSDD, a significant unmet medical need.